chrisvoncsefalvay/vaers-outcomes huggingface dataset:
diarrhea; slept all day; couldn't eat or drink water; tiredness; body ache; headache; vomiting; This spontaneous case was reported by a consumer and describes the occurrence of DIARRHOEA (diarrhea), SLEEP DISORDER (slept all day), DECREASED APPETITE (couldn't eat or drink water), HEADACHE (headache) and VOMITING (vomiting) in a 49-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 036A21A and 008B21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.   On 05-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 02-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 05-Mar-2021, the patient experienced HEADACHE (headache) and VOMITING (vomiting). On 03-Apr-2021, the patient experienced MYALGIA (body ache). On 05-Apr-2021, the patient experienced DIARRHOEA (diarrhea), SLEEP DISORDER (slept all day), DECREASED APPETITE (couldn't eat or drink water) and FATIGUE (tiredness). The patient was treated with PARACETAMOL (TYLENOL) for Adverse event, at an unspecified dose and frequency. On 03-Apr-2021, MYALGIA (body ache) had resolved. On 05-Apr-2021, DIARRHOEA (diarrhea), SLEEP DISORDER (slept all day), DECREASED APPETITE (couldn't eat or drink water) and FATIGUE (tiredness) had resolved. At the time of the report, HEADACHE (headache) and VOMITING (vomiting) outcome was unknown.            No concomitant medication was provided.   This case was linked to US-MODERNATX, INC.-MOD-2021-068534 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2021-068534:crosslinked with first dose
Approx. 5 minutes of eyes rolled up, vomiting.  Concern for seizure activity.  Temperature 38.8. Spontaneously resolved, evaluated at Medical Center Emergency Department by Dr.
Expired vaccine used; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Expired vaccine used) in a 72-year-old patient of an unknown gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 021B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 11-Nov-2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .25 ml. On 11-Nov-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (Expired vaccine used). On 11-Nov-2021, EXPIRED PRODUCT ADMINISTERED (Expired vaccine used) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No Concomitant and Treatment medication were reported.   This case was linked to MOD-2021-405735, MOD-2021-399960, MOD-2021-405538, MOD-2021-405545, MOD-2021-405585, MOD-2021-405622, MOD-2021-405652, MOD-2021-405659, MOD-2021-405696, MOD-2021-405721 (Patient Link).
This spontaneous report was received from a pharmacist referring to a patient of unknown age or gender. The patient's concurrent conditions, medical history or concomitant medication were not reported. On 02-MAY-2017, the patient was inadvertently vaccinated with an expired dose of PNEUMOVAX 23 with lot # L029113 and an expiration date of 27-MAR-2017. There was no adverse event was reported. Additional information has been requested.
7 hours after the shot I began to feel very tired and sluggish. I also developed a headache. At the 10 hour mark, I was experiencing body aches, severe headache, fever, chills, and nausea. After 36 hours, I am still experiencing muscle aches, headache, fever, and joint pain.
Starting one week after shot - on 4/15/21 - Accelerated heartbeat - out of rhythm heartbeat.  Continued to get worse,  Hospitalized on 4/21/21.  Diagnosed with AFib, Heartrate over 170 bpm -
Middle to night after admin. woke up with severe hives/welts on legs/torso.
11/29/21  presenting today for Cough (sneezing cough tested positive at home covid ) and Covid-19 Positive  51 year old female here today with c/o cough, sneezing x 7 days. States had positive home covid test 7 days ago. States she had known covid exposure about 2 weeks prior to her symptoms starting. She states no fever. She states she has gotten covid, flu vaccines.    Review of Systems  Constitutional: Negative for activity change, appetite change, chills, diaphoresis, fatigue and fever.  HENT: Positive for sneezing. Negative for congestion, ear pain, postnasal drip, rhinorrhea, sinus pressure, sinus pain, sore throat, tinnitus, trouble swallowing and voice change.   11/29/21  Eyes: Negative for photophobia, pain, discharge, redness and itching.  Respiratory: Positive for cough. Negative for chest tightness, shortness of breath, wheezing and stridor.   Cardiovascular: Negative for chest pain, palpitations and leg swelling.  Gastrointestinal: Negative for abdominal pain, diarrhea, nausea and vomiting.  Genitourinary: Negative for decreased urine volume.  Musculoskeletal: Negative for myalgias, neck pain and neck stiffness.  Skin: Negative for rash.  Neurological: Negative for dizziness, weakness and headaches.
My right foot felt like it was asleep; Tingling in her right leg; rash on her right leg; More than 35 days since the patient received her first Moderna Covid-19 vaccine; Tinnitus; Fever; Chills; This spontaneous case was reported by a consumer and describes the occurrence of PYREXIA (Fever), CHILLS (Chills), TINNITUS (Tinnitus), PARAESTHESIA (Tingling in her right leg) and RASH (rash on her right leg) in a 46-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 007C21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On 20-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 20-Apr-2021, the patient experienced PYREXIA (Fever) and CHILLS (Chills). On 22-Apr-2021, the patient experienced TINNITUS (Tinnitus). On 23-Apr-2021, the patient experienced PARAESTHESIA (Tingling in her right leg), RASH (rash on her right leg) and PRODUCT DOSE OMISSION ISSUE (More than 35 days since the patient received her first Moderna Covid-19 vaccine). On an unknown date, the patient experienced HYPOAESTHESIA (My right foot felt like it was asleep). At the time of the report, PYREXIA (Fever), CHILLS (Chills), TINNITUS (Tinnitus), PARAESTHESIA (Tingling in her right leg), RASH (rash on her right leg), PRODUCT DOSE OMISSION ISSUE (More than 35 days since the patient received her first Moderna Covid-19 vaccine) and HYPOAESTHESIA (My right foot felt like it was asleep) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   no treatment drugs included no concomitant drugs included
Information has been received from a pharmacist concerning a teenage female pt who in approx. 2001, was vaccinated with a dose of pneumococcal vaccine 23 polyvalent. Subsequently, the pt fainted. It was reported that the next day, the pt was fine and went to school. Unspecified medical attention was sought. Additional information has been requested.
temp high on 17JAN92 rash all over body still present fading somewhat; coughing;
Covid arm; a big red oval around the injection site; itchy; extra sore compared to the 1st 2 shots and tenderness; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE REACTION (Covid arm), VACCINATION SITE ERYTHEMA (a big red oval around the injection site), VACCINATION SITE PRURITUS (itchy) and VACCINATION SITE PAIN (extra sore compared to the 1st 2 shots and tenderness) in a 78-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 047C21A, 001021A and 031M20A) for COVID-19 vaccination.     Concomitant products included INFLUENZA VACCINE (FLU) for an unknown indication.   On 12-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 12-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 28-Oct-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. In 2021, the patient experienced VACCINATION SITE REACTION (Covid arm), VACCINATION SITE ERYTHEMA (a big red oval around the injection site), VACCINATION SITE PRURITUS (itchy) and VACCINATION SITE PAIN (extra sore compared to the 1st 2 shots and tenderness). The patient was treated with CALAMINE for Adverse event, at an unspecified dose and frequency. At the time of the report, VACCINATION SITE REACTION (Covid arm) and VACCINATION SITE PAIN (extra sore compared to the 1st 2 shots and tenderness) outcome was unknown and VACCINATION SITE ERYTHEMA (a big red oval around the injection site) and VACCINATION SITE PRURITUS (itchy) was resolving.            This case was linked to MOD-2021-370373, MOD-2021-370374 (Patient Link).
On Apr. 3 I had vertigo and fell on my back in the bedroom. 15 minutes later I started vomiting and nausea and then went to the Emergency room.  Hospitalized for 5 days.  Discharged on Apr. 7 but still very weak and need help getting up or lying down.
Information has been received from a physician concerning an approximately 23 week old male infant who on 07-JUL-2008 was vaccinated orally with a second dose of ROTATEQ (lot # 660600/0281X). The first dose of ROTATEQ (lot # 660376/0019X) was given on 05-MAY-2008. Concomitant vaccinations on the same day as the second dose (07-JUL-2008) included DTaP, PREVNAR, poliovirus vaccine inactivated (unspecified) (manufacturer unknown) and Hib conj vaccine (manufacturer unknown). It was noted that the patient experienced diarrhea, vomiting, and a fever of 102.7 approximately 4-5 days before being admitted to the hospital on 10-AUG-2008. The patient's stool cultures were negative. On 12-AUG-2008, the patient was discharged from the hospital. Subsequently, the patient recovered on an unspecified date. Additional information has been requested.
Immediately following the vaccine, patient began limping and crying. Was limping until bed time. Woke up on 5/21 still limping. 5/22 developed warm to the touch visibly red thigh. The whole thigh area is visibly swollen, red and warm and is still painful.
Patient had swelling of face/puffy eyes, came to ER and admitted, and was treated as facial cellulitis -- but there could be an element of angioedema
client received astrazeneca covid vaccine, no reaction. Previous vaccine unavailable in the  Janssen given as an alternative on 9/15/21
Dtap given on 7/18/15, on 7-19-15 dad noticed red, swollen area were vaccine given, and returned to office for visit on 7-20-15.
Patient received the vaccine in the morning.  That evening  developed hives on bilateral posterior legs.  Was given loratadine and pepcid at an urgent care center and the hives resolved the following day.
After receiving the covid vaccine I developed symptoms of hypothyroidism: Dry skin, Exercise fatigue, Cold intolerance, Fatigue & Weight gain. On Dec.28, 2021 I had labs drawn which included TSH and saw my doctor on Jan 6,  2022. She started me on levothyroxine and ordered more labs which were drawn on Feb, 17. My next office visit was Feb 24 and my most recent labs showed Hashimotos hypothyroisism which was brought under control with the levothyroxine.
Missed the second part of immunization record which shows patient received already Flu shot 10/7/16 and was given the second FLUVIRIN 12/27/16.
Patient was given Moderna  instead of the needed second dose of Pfizer.  Patient was given Pfizer dose 1 on 1/23/2021 and should have received Pfizer dose 2 on 2/13/2021. Patient was given Moderna on 2/13/2021 in error.
Treatment of COVID-19; Treatment of COVID-19; This is a spontaneous report received from a contactable reporter (Consumer or other non HCP). The reporter is the patient.  A 50-year-old female patient (not pregnant) received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 28Oct2022 as dose 4 (booster), single (Lot number: GJ2524) at the age of 50 years, in right arm for COVID-19 immunisation; BNT162b2 (BNT162B2), on 19Feb2021 as dose 1, single (Lot number: EM9809), in left arm, on 12Mar2021 as dose 2, single (Lot number: EN6198), in left arm and on 20Oct2021 as dose 3 (booster), single (Lot number: 30130BA), in left arm for COVID-19 immunisation. The patient's relevant medical history included: "Hypertension" (unspecified if ongoing); "Known allergies: Latex" (unspecified if ongoing). Concomitant medication included: LISINOPRIL, start date: 25Aug2016. Past drug history included: Codeine, reaction: "Known allergy". The following information was reported: VACCINATION FAILURE (medically significant), COVID-19 (medically significant), outcome "unknown" and all described as "Treatment of COVID-19". Therapeutic measures were taken as a result of vaccination failure, COVID-19 which included Paxlovid started on 19Feb2023.
Information has been received from a registered nurse regarding a patient of an unknown age and gender. On 01-JUL-2013 at 07:40, ZOSTAVAX lot # J001005 was exposed to an exact T not recorded but noted as equal to or >12C for an estimated total time out of range 44.5 hours. On 01-AUG-2013 at 07:40, ZOSTAVAX lot # J001005 was exposed to -12C for an estimated total time out of range of 14 hours. On 13-AUG-2013, the patient was vaccinated with an out of range dose of ZOSTAVAX (dose and route administration were not provided) (Lot number J001005, Exp. Date: 24-APR-2014). No adverse experience had been reported. This is one of 182 reports from the same source. Additional information has been requested.
Diagnosed with bladder cancer 4 months after receiving the Covid-19 vaccine. No previous history of bladder cancer or bladder problems.
Quarter size red area 24 hours after injection. One day later, redness increase to triple size, warm and firm to touch. (6.75 x 5 cm).
Patient age 17 was administered Moderna vaccine.  Age limit for Moderna is 18.
patient received Shingrix doses, then developed shingles on 17Sep2021/suspected vaccination failure; developed shingles on 17Sep2021; This case was reported by a pharmacist via call center representative and described the occurrence of vaccination failure in a 66-year-old female patient who received Herpes zoster (Shingrix) (batch number G7274, expiry date 13th March 2022) for prophylaxis.   Co-suspect products included Herpes zoster (Shingrix) (batch number 7F33X, expiry date 11th December 2021) for prophylaxis.   Concurrent medical conditions included rheumatoid arthritis. Concomitant products included tofacitinib citrate (Xeljanz).   On 24th February 2020, the patient received the 2nd dose of Shingrix. On 7th November 2019, the patient received the 1st dose of Shingrix. On 17th September 2021, 571 days after receiving Shingrix and 680 days after receiving Shingrix, the patient experienced vaccination failure (serious criteria GSK medically significant) and shingles. On an unknown date, the outcome of the vaccination failure and shingles were unknown.   It was unknown if the reporter considered the vaccination failure and shingles to be related to Shingrix and Shingrix.     Additional Information: GSK Receipt Date: 18-MAY-2022 Reporter's Comment: The patient was diagnosed with Rheumatoid Arthritis and started on immunosuppressant medication Xeljanz prior to receiving Shingrix series. Pharmacist reported that the patient received 2 doses of Shingrix and she then developed shingles.   The reporter consented to follow up. Additional Supportive Information: This case described the occurrence of suspected vaccination failure. This case was considered as suspected vaccination failure as details regarding laboratory test confirming shingles was unknown at the time of reporting.
Initial and follow-up info has been received from a nurse practitioner concerning a "healthy," obese female pt who was vaccinated with measles virus vaccine SC on 04/08/2002. The pt had no previous past medical history of problems with vaccines, had a negative measles titer and was immunized on 04/08/2002 with measles vaccine. On 04/16/2002, the pt first noted redness on her right arm. On 04/17/2002, the pt called the office complaining of redness at the injection site and called the office again later that day, reporting that the redness was worsening. On 04/18/2002, the pt notified the office that the injection site was not improving and was assessed by the nurse practitioner that same day. The nurse practitioner described the pt's arm as red, swollen and hot and was diagnosed with a large, suspected cellulitus of the right arm. Dicloxacillin therapy was prescribed for the pt and was instructed to elevate her arm. The pt was scheduled to leave for a trip on 04/20/2002 and she was instructed to cancel her trip due to her arm condition. The pt reported to the nurse practitioner on 04/22/2002 that her erythema was decreasing and she was instructed to continue dicloxacillin therapy. On 04/23/2002, the pt visited the nurse practitioner again and her erythema was worsening. It was redder, and hotter with new areas appearing. The pt had the following lab values performed on 04/23/2002: Measles titer-pending; elevated sedementation rate, normal WBC count; elevated CRP. An HIV test was not performed because the pt had no risk factors. The pt was scheduled to leave for a trip on 04/24/2002; however, she cancelled the trip and the nurse practitioner stated that the airlines refused to refund the pt's money. The nurse practitioner also stated that the physicians are going to write a letter to get the pt reimbursd for her cancelled trip. The nurse practitioner stated that the pt's final diagnosis was  an atypical measles reaction and the dicloxacilin therapy provided no relief. The nurse practitioner also stated that the pt's cellulitis of right arm and atypical measles reaction were considered other medical events and were serious since the pt had to cancel her trip. The nurse practitioner also discussed the events of a male pt who was vaccinated with measles virus vaccine from the same lot and she was concerned about the particular lot of vaccine. The nurse practitioner also stated that her records indicate that in the past year she had given the measles vaccine a total of eight times from that lot and two fo the eight pts had had adverse reactions. The records of testing prior to release of this lot have been checked and found to be satisfactory. The lot complies with the standards of the Center for Biologics Evaluation and Research and was released. Additional info is not expected.
Within 25 min of receiving the shot my head began to feel tingly and felt like pins and needles going up my neck and head.  I then began to feel very hot and turn red.  After about 2 minutes I noticed that my body had broken out in hives. This lasted for about an hour.
The only symptom I have is chronic tenderness of both injection sites.  Sometimes it feels very warm, sometimes it throbs. Unrelated in my opinion is the fact that I have been diagnosed with a torn rotator cuff on this same shoulder.  However, the discomfort is completely different.
One and a half hours after I received my injection, while driving home, my mouth, lips and face began to tingle.  This lasted for almost two hours.  I experienced some brief tingling of the skin on my chest as well and on the skin of my upper thighs.  I did not have trouble breathing, and did not develop a rash anywhere on my body.  The tingling remained localized to my face and the upper part of my mouth.   There was no swelling of my lips or redness of my lips.  Immediately after I received my injection I briefly felt the slightest bit of light headedness, but this resolved before I left the vaccination site.   I felt tired later in the evening and then began to experience headache and nausea, the typical side effects that I had anticipated and previously heard about.
Patient developed hives and rash around injection site.  Area was 4 X 4 red warm to the touch.
Patient received a Moderna booster 3/15/22 around 1600.  Calls 3/17/22 reporting many side effects: 3/15/22  arm pain 5-6 times worse than first dose;  3 hours after shot numbness and tingling in hands, felt a "happiness" in head for about 30 minutes 3/16/22 0300- woke up with chills; temp 100.4 at 0600 with terrible HA, arm pain and stomach ache; stayed home from work; at about 1130 he felt dizzy and the next thing he saw was his father was standing over him as he had fainted
PT EXP PAIN AND STINGING AT SOI AFTER ENGERIX-B.  TREATMENT:  PT COUNSELING.
Patient under 65 received Fluad QIV; Feeling cold; Generalized malaise; Joint pain; Muscle ache; This spontaneous case received on 05-Nov-2020 from other health professional (nurse) via Agency (reference number: SEQW20-04825) and concerned a 38-year-old, female patient.   The patient had no relevant medical history. The patient's concomitant medications were not reported.   On 29-Sep-2020, the patient was vaccinated with Fluad Quadrivalent (influenza vaccine, inactivated influenza virus surface antigen (subunit), egg-derived, MF59; dose: 0.5 ml, route of administration: intramuscular, anatomical location: deltoid) (explicitly coded as 'Inappropriate age at vaccine administration') for influenza prophylaxis. The batch number reported was 286592.  On an unspecified date, an unknown amount of time after receiving Fluad Quadrivalent, the patient experienced generalized malaise, joint pain, muscle aches, and was feeling cold. The patient started treatment with Tylenol (paracetamol).  The outcome of the events was not reported.  The reporter did not provide causality assessment.  The reporter assessed the case as non-serious.   This case is linked with the cases 202004845, 202006067, 202006068, 202006069, 202006072, 202006074, 202006077, 202006078, 202006079, 202006080, 202006081, 202006084, 202006085, 202006086, 202006087, 202006088, 202006089, 202006090, 202006092, 202006093, 202006095, 202006096, 202006097, 202006099 (the same reporter).  Company comment: A 38-year-old, female patient was vaccinated with Fluad Quadrivalent. An unknown amount of time after receiving Fluad Quadrivalent, the patient experienced malaise, arthralgia, myalgia and was feeling cold. With information available, causal role of the suspect vaccine is assessed as possibly. Product administered to patient of inappropriate age is assessed as not related, per company's conventions.; Sender's Comments: A 38-year-old, female patient was vaccinated with Fluad Quadrivalent. An unknown amount of time after receiving Fluad Quadrivalent, the patient experienced malaise, arthralgia, myalgia and was feeling cold. With information available, causal role of the suspect vaccine is assessed as possibly. Product administered to patient of inappropriate age is assessed as not related, per company's conventions.